AML research hub

A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

This study looks at a new combination treatment for adults with a type of blood cancer called AML that has come back or not responded to previous treatment. It aims to see if adding gilteritinib to standard drugs is safe and works better.